Plain-English translation of NCT06130787 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This French research study is testing whether measuring your biological age — determined through a blood test that looks at your DNA — along with your overall health and frailty status can help doctors personalize your chronic myeloid leukemia treatment. You'll be newly diagnosed and starting tyrosine kinase inhibitor therapy, the standard first-line medication for this condition. The study wants to see if these measurements can help predict who will do best on the medication and how to tailor care to your individual needs.
Doctors know that patients respond differently to the same leukemia treatment, and age alone doesn't always explain why. This trial explores whether measuring your biological age — how fast your cells are aging — along with your physical health status could help doctors choose the best treatment plan specifically for you.
You likely qualify if…
You likely don't qualify if…
You'll attend follow-up visits where researchers will collect blood samples for DNA analysis to measure your biological age and assess your physical health and frailty using standard geriatric health tools. These assessments will happen alongside your regular leukemia treatment and monitoring appointments. The study involves multiple French medical centers and will track your health over time to see how biological age relates to your response to the medication.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France